Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026

GlobeNewswire

WALTHAM, Mass., Sept. 06, 2026 -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension.

  1. MRI Patients Want to Keep Their Respirators On. ReadiMask Gives Technologists Independent MR Safe DocumentationMED Institute independently determined ReadiMask meets MR Safe under ASTM F2503-26, giving MRI patients documentation to keep masks on.
  2. Kinvestor Day 2026 Virtual Investor Conference Schedule Announced for October 22, 2026Kin Communications Inc. announces the agenda for its Kinvestor Day 2026 Virtual Investor Conference on October 22, 2026.
  3. New Cangrade Research Reveals Growing Divide Between Individual Performance and Leadership Skills Among Gen Z and MillennialsNew research from Cangrade analyzes more than 71,000 real-world job assessments to uncover the capabilities of millennial and Gen Z workers.
  4. Canadian Investment Regulatory Organization Trading Halt - MAK.UThe following issues have been halted by CIRO :
  5. Kite Hill Recognized as a 2026 Inc. Power Partner Award Winner for the Second Consecutive YearThe annual Inc. Power Partner Award recognizes B2B companies that provide essential services and expertise to help entrepreneurs and businesses grow
  6. SaaSCreative Medical Technology Holdings, Inc.Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis StudyInternational Scientific Presentation Underscores Encouraging Clinical Outcomes and Additional Biological Potency Findings Supporting Cell-Free Regenerative Platform